ID   PKN1_HUMAN              Reviewed;         942 AA.
AC   Q16512; A8K7W5; B2R9R4; B3KVN3; Q15143; Q504U4; Q8IUV5; Q9UD44;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   22-SEP-2009, sequence version 2.
DT   12-OCT-2022, entry version 235.
DE   RecName: Full=Serine/threonine-protein kinase N1;
DE            EC=2.7.11.13 {ECO:0000269|PubMed:18066052};
DE   AltName: Full=Protease-activated kinase 1;
DE            Short=PAK-1;
DE   AltName: Full=Protein kinase C-like 1;
DE   AltName: Full=Protein kinase C-like PKN;
DE   AltName: Full=Protein kinase PKN-alpha;
DE   AltName: Full=Protein-kinase C-related kinase 1;
DE   AltName: Full=Serine-threonine protein kinase N;
GN   Name=PKN1; Synonyms=PAK1, PKN, PRK1, PRKCL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF LYS-644.
RC   TISSUE=Hippocampus;
RX   PubMed=8135837; DOI=10.1006/bbrc.1994.1313;
RA   Mukai H., Ono Y.;
RT   "A novel protein kinase with leucine zipper-like sequences: its catalytic
RT   domain is highly homologous to that of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 199:897-904(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=7851406; DOI=10.1111/j.1432-1033.1995.tb20395.x;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Cloning and expression patterns of two members of a novel protein-kinase-
RT   C-related kinase family.";
RL   Eur. J. Biochem. 227:344-351(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   ILE-555 AND ILE-901.
RC   TISSUE=Kidney, Synovium, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   ILE-901.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 700-800 (ISOFORMS 1/2), AND VARIANT VAL-718.
RX   PubMed=7988719; DOI=10.1016/0014-5793(94)01202-4;
RA   Palmer R.H., Ridden J., Parker P.J.;
RT   "Identification of multiple, novel, protein kinase C-related gene
RT   products.";
RL   FEBS Lett. 356:5-8(1994).
RN   [7]
RP   FUNCTION.
RX   PubMed=8557118; DOI=10.1016/0014-5793(95)01454-3;
RA   Palmer R.H., Schonwasser D.C., Rahman D., Pappin D.J., Herget T.,
RA   Parker P.J.;
RT   "PRK1 phosphorylates MARCKS at the PKC sites: serine 152, serine 156 and
RT   serine 163.";
RL   FEBS Lett. 378:281-285(1996).
RN   [8]
RP   FUNCTION.
RX   PubMed=8621664; DOI=10.1074/jbc.271.16.9816;
RA   Mukai H., Toshimori M., Shibata H., Kitagawa M., Shimakawa M., Miyahara M.,
RA   Sunakawa H., Ono Y.;
RT   "PKN associates and phosphorylates the head-rod domain of neurofilament
RT   protein.";
RL   J. Biol. Chem. 271:9816-9822(1996).
RN   [9]
RP   ACTIVITY REGULATION, AND INTERACTION WITH RHOA.
RX   PubMed=8571126; DOI=10.1126/science.271.5249.645;
RA   Watanabe G., Saito Y., Madaule P., Ishizaki T., Fujisawa K., Morii N.,
RA   Mukai H., Ono Y., Kakizuka A., Narumiya S.;
RT   "Protein kinase N (PKN) and PKN-related protein rhophilin as targets of
RT   small GTPase Rho.";
RL   Science 271:645-648(1996).
RN   [10]
RP   FUNCTION.
RX   PubMed=9175763; DOI=10.1006/bbrc.1997.6669;
RA   Matsuzawa K., Kosako H., Inagaki N., Shibata H., Mukai H., Ono Y.,
RA   Amano M., Kaibuchi K., Matsuura Y., Azuma I., Inagaki M.;
RT   "Domain-specific phosphorylation of vimentin and glial fibrillary acidic
RT   protein by PKN.";
RL   Biochem. Biophys. Res. Commun. 234:621-625(1997).
RN   [11]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH RHOB.
RX   PubMed=9478917; DOI=10.1074/jbc.273.9.4811;
RA   Mellor H., Flynn P., Nobes C.D., Hall A., Parker P.J.;
RT   "PRK1 is targeted to endosomes by the small GTPase, RhoB.";
RL   J. Biol. Chem. 273:4811-4814(1998).
RN   [12]
RP   ACTIVITY REGULATION, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF ASP-108;
RP   ASP-451; ASP-454; ASP-558 AND ASP-560.
RX   PubMed=9751706; DOI=10.1073/pnas.95.20.11566;
RA   Takahashi M., Mukai H., Toshimori M., Miyamoto M., Ono Y.;
RT   "Proteolytic activation of PKN by caspase-3 or related protease during
RT   apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11566-11571(1998).
RN   [13]
RP   PHOSPHORYLATION AT THR-774 BY PDPK1, AND INTERACTION WITH PDPK1.
RX   PubMed=10792047; DOI=10.1073/pnas.090491897;
RA   Dong L.Q., Landa L.R., Wick M.J., Zhu L., Mukai H., Ono Y., Liu F.;
RT   "Phosphorylation of protein kinase N by phosphoinositide-dependent protein
RT   kinase-1 mediates insulin signals to the actin cytoskeleton.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5089-5094(2000).
RN   [14]
RP   FUNCTION.
RX   PubMed=11104762; DOI=10.1074/jbc.m007427200;
RA   Taniguchi T., Kawamata T., Mukai H., Hasegawa H., Isagawa T., Yasuda M.,
RA   Hashimoto T., Terashima A., Nakai M., Mori H., Ono Y., Tanaka C.;
RT   "Phosphorylation of tau is regulated by PKN.";
RL   J. Biol. Chem. 276:10025-10031(2001).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH AR.
RX   PubMed=12514133; DOI=10.1093/emboj/cdg023;
RA   Metzger E., Muller J.M., Ferrari S., Buettner R., Schule R.;
RT   "A novel inducible transactivation domain in the androgen receptor:
RT   implications for PRK in prostate cancer.";
RL   EMBO J. 22:270-280(2003).
RN   [16]
RP   INTERACTION WITH S.TYPHIMURIUM SSPH1 (MICROBIAL INFECTION).
RX   PubMed=16611232; DOI=10.1111/j.1462-5822.2005.00670.x;
RA   Haraga A., Miller S.I.;
RT   "A Salmonella type III secretion effector interacts with the mammalian
RT   serine/threonine protein kinase PKN1.";
RL   Cell. Microbiol. 8:837-846(2006).
RN   [17]
RP   INTERACTION WITH CCNT2.
RX   PubMed=16331689; DOI=10.1002/jcp.20566;
RA   Cottone G., Baldi A., Palescandolo E., Manente L., Penta R., Paggi M.G.,
RA   De Luca A.;
RT   "Pkn is a novel partner of cyclin T2a in muscle differentiation.";
RL   J. Cell. Physiol. 207:232-237(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533 AND SER-562, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [19]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=17332740; DOI=10.1038/sj.emboj.7601637;
RA   Schmidt A., Durgan J., Magalhaes A., Hall A.;
RT   "Rho GTPases regulate PRK2/PKN2 to control entry into mitosis and exit from
RT   cytokinesis.";
RL   EMBO J. 26:1624-1636(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-778, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205 AND SER-537, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-644.
RX   PubMed=18066052; DOI=10.1038/ncb1668;
RA   Metzger E., Yin N., Wissmann M., Kunowska N., Fischer K., Friedrichs N.,
RA   Patnaik D., Higgins J.M., Potier N., Scheidtmann K.H., Buettner R.,
RA   Schule R.;
RT   "Phosphorylation of histone H3 at threonine 11 establishes a novel
RT   chromatin mark for transcriptional regulation.";
RL   Nat. Cell Biol. 10:53-60(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537; SER-559;
RP   SER-562 AND SER-916, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-205; SER-533; SER-537;
RP   SER-559; SER-562; THR-914 AND SER-916, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-448, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [27]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=20188095; DOI=10.1016/j.febslet.2010.02.057;
RA   Harrison B.C., Huynh K., Lundgaard G.L., Helmke S.M., Perryman M.B.,
RA   McKinsey T.A.;
RT   "Protein kinase C-related kinase targets nuclear localization signals in a
RT   subset of class IIa histone deacetylases.";
RL   FEBS Lett. 584:1103-1110(2010).
RN   [28]
RP   INTERACTION WITH PRKCB.
RX   PubMed=20228790; DOI=10.1038/nature08839;
RA   Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N.,
RA   Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N.,
RA   Beisenherz-Huss C., Gunther T., Buettner R., Schule R.;
RT   "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at
RT   histone H3K4.";
RL   Nature 464:792-796(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-533; SER-537 AND SER-562, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH AKAP13; MAPK14; ZAK AND
RP   MAP2K3.
RX   PubMed=21224381; DOI=10.1074/jbc.m110.185645;
RA   Cariolato L., Cavin S., Diviani D.;
RT   "A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling
RT   complex involved in alpha1-adrenergic receptor-induced p38 activation.";
RL   J. Biol. Chem. 286:7925-7937(2011).
RN   [32]
RP   FUNCTION IN CELL MIGRATION, AND TISSUE SPECIFICITY.
RX   PubMed=21754995; DOI=10.1371/journal.pone.0021732;
RA   Lachmann S., Jevons A., De Rycker M., Casamassima A., Radtke S.,
RA   Collazos A., Parker P.J.;
RT   "Regulatory domain selectivity in the cell-type specific PKN-dependence of
RT   cell migration.";
RL   PLoS ONE 6:E21732-E21732(2011).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-562, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-69; SER-533; SER-537;
RP   SER-540; SER-562; SER-608 AND SER-916, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-916, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98 IN COMPLEX WITH RHOA.
RX   PubMed=10619026; DOI=10.1016/s1097-2765(00)80389-5;
RA   Maesaki R., Ihara K., Shimizu T., Kuroda S., Kaibuchi K., Hakoshima T.;
RT   "The structural basis of Rho effector recognition revealed by the crystal
RT   structure of human RhoA complexed with the effector domain of PKN/PRK1.";
RL   Mol. Cell 4:793-803(1999).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 13-98.
RX   PubMed=10388627; DOI=10.1006/jsbi.1999.4114;
RA   Maesaki R., Shimizu T., Ihara K., Kuroda S., Kaibuchi K., Hakoshima T.;
RT   "Biochemical and crystallographic characterization of a Rho effector domain
RT   of the protein serine/threonine kinase N in a complex with RhoA.";
RL   J. Struct. Biol. 126:166-170(1999).
RN   [39]
RP   STRUCTURE BY NMR OF 116-199 IN COMPLEX WITH RAC1.
RX   PubMed=14514689; DOI=10.1074/jbc.m304313200;
RA   Owen D., Lowe P.N., Nietlispach D., Brosnan C.E., Chirgadze D.Y.,
RA   Parker P.J., Blundell T.L., Mott H.R.;
RT   "Molecular dissection of the interaction between the small G proteins Rac1
RT   and RhoA and protein kinase C-related kinase 1 (PRK1).";
RL   J. Biol. Chem. 278:50578-50587(2003).
RN   [40]
RP   STRUCTURE BY NMR OF 122-199 IN COMPLEX WITH RAC1.
RX   PubMed=18006505; DOI=10.1074/jbc.m706760200;
RA   Modha R., Campbell L.J., Nietlispach D., Buhecha H.R., Owen D., Mott H.R.;
RT   "The Rac1 polybasic region is required for interaction with its effector
RT   PRK1.";
RL   J. Biol. Chem. 283:1492-1500(2008).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 122-199 IN COMPLEX WITH
RP   SALMONELLA SSPH1, UBIQUITINATION (MICROBIAL INFECTION), MUTAGENESIS OF
RP   ARG-181 AND ARG-185, FUNCTION AS ANDROGEN RECEPTOR COACTIVATOR, AND
RP   INTERACTION WITH SALMONELLA SSPH1 (MICROBIAL INFECTION).
RX   PubMed=24248594; DOI=10.1128/mcb.01360-13;
RA   Keszei A.F., Tang X., McCormick C., Zeqiraj E., Rohde J.R., Tyers M.,
RA   Sicheri F.;
RT   "Structure of an SspH1-PKN1 complex reveals the basis for host substrate
RT   recognition and mechanism of activation for a bacterial E3 ubiquitin
RT   ligase.";
RL   Mol. Cell. Biol. 34:362-373(2014).
RN   [42]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-185; GLU-197; TRP-436; GLN-520;
RP   ILE-555; GLN-635; VAL-718; LEU-873; ILE-901 AND VAL-921.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: PKC-related serine/threonine-protein kinase involved in
CC       various processes such as regulation of the intermediate filaments of
CC       the actin cytoskeleton, cell migration, tumor cell invasion and
CC       transcription regulation. Part of a signaling cascade that begins with
CC       the activation of the adrenergic receptor ADRA1B and leads to the
CC       activation of MAPK14. Regulates the cytoskeletal network by
CC       phosphorylating proteins such as VIM and neurofilament proteins NEFH,
CC       NEFL and NEFM, leading to inhibit their polymerization. Phosphorylates
CC       'Ser-575', 'Ser-637' and 'Ser-669' of MAPT/Tau, lowering its ability to
CC       bind to microtubules, resulting in disruption of tubulin assembly. Acts
CC       as a key coactivator of androgen receptor (AR)-dependent transcription,
CC       by being recruited to AR target genes and specifically mediating
CC       phosphorylation of 'Thr-11' of histone H3 (H3T11ph), a specific tag for
CC       epigenetic transcriptional activation that promotes demethylation of
CC       histone H3 'Lys-9' (H3K9me) by KDM4C/JMJD2C. Phosphorylates HDAC5,
CC       HDAC7 and HDAC9, leading to impair their import in the nucleus.
CC       Phosphorylates 'Thr-38' of PPP1R14A, 'Ser-159', 'Ser-163' and 'Ser-170'
CC       of MARCKS, and GFAP. Able to phosphorylate RPS6 in vitro.
CC       {ECO:0000269|PubMed:11104762, ECO:0000269|PubMed:12514133,
CC       ECO:0000269|PubMed:17332740, ECO:0000269|PubMed:18066052,
CC       ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:21224381,
CC       ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:24248594,
CC       ECO:0000269|PubMed:8557118, ECO:0000269|PubMed:8621664,
CC       ECO:0000269|PubMed:9175763}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC         Evidence={ECO:0000269|PubMed:18066052};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13; Evidence={ECO:0000269|PubMed:18066052};
CC   -!- ACTIVITY REGULATION: Kinase activity is activated upon binding to Rho
CC       proteins (RHOA, RHOB and RAC1). Activated by lipids, particularly
CC       cardiolipin and to a lesser extent by other acidic phospholipids.
CC       Activated by caspase-3 (CASP3) cleavage during apoptosis. Two specific
CC       sites, Thr-774 (activation loop of the kinase domain) and Ser-916 (turn
CC       motif), need to be phosphorylated for its full activation.
CC       {ECO:0000269|PubMed:8571126, ECO:0000269|PubMed:9751706}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=20.6 uM for HDAC5 {ECO:0000269|PubMed:20188095};
CC   -!- SUBUNIT: Interacts with ZFAND6 (By similarity). Interacts with AR
CC       (PubMed:12514133). Interacts with PRKCB (PubMed:20228790). Interacts
CC       (via REM 1 and REM 2 repeats) with RAC1 (PubMed:14514689,
CC       PubMed:18006505). Interacts (via REM 1 repeat) with RHOA
CC       (PubMed:10619026, PubMed:8571126). Interacts with RHOB
CC       (PubMed:9478917). Interacts (via C-terminus) with PDPK1
CC       (PubMed:10792047). Interacts with CCNT2; enhances MYOD1-dependent
CC       transcription (PubMed:16331689). Component of a signaling complex
CC       containing at least AKAP13, PKN1, MAPK14, ZAK and MAP2K3. Within this
CC       complex, AKAP13 interacts directly with PKN1, which in turn recruits
CC       MAPK14, MAP2K3 and ZAK (PubMed:21224381).
CC       {ECO:0000250|UniProtKB:P70268, ECO:0000269|PubMed:10619026,
CC       ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:12514133,
CC       ECO:0000269|PubMed:14514689, ECO:0000269|PubMed:16331689,
CC       ECO:0000269|PubMed:18006505, ECO:0000269|PubMed:20228790,
CC       ECO:0000269|PubMed:21224381, ECO:0000269|PubMed:8571126,
CC       ECO:0000269|PubMed:9478917}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via the second REM repeat)
CC       with S.typhimurium E3 ubiquitin-protein ligase SspH1 (via the leucine-
CC       rich repeat region) (PubMed:16611232, PubMed:24248594).
CC       {ECO:0000269|PubMed:16611232, ECO:0000269|PubMed:24248594}.
CC   -!- INTERACTION:
CC       Q16512; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-602382, EBI-10173507;
CC       Q16512; Q9ULX6: AKAP8L; NbExp=3; IntAct=EBI-602382, EBI-357530;
CC       Q16512; Q6PJH3: AKAP9; NbExp=3; IntAct=EBI-602382, EBI-11745576;
CC       Q16512; P05067: APP; NbExp=3; IntAct=EBI-602382, EBI-77613;
CC       Q16512; P15289: ARSA; NbExp=3; IntAct=EBI-602382, EBI-2117357;
CC       Q16512; Q14457: BECN1; NbExp=3; IntAct=EBI-602382, EBI-949378;
CC       Q16512; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-602382, EBI-2548012;
CC       Q16512; Q8WU43: C2orf15; NbExp=3; IntAct=EBI-602382, EBI-12904676;
CC       Q16512; Q8IW40: CCDC103; NbExp=3; IntAct=EBI-602382, EBI-10261970;
CC       Q16512; Q96M89-2: CCDC138; NbExp=3; IntAct=EBI-602382, EBI-10972887;
CC       Q16512; Q15834: CCDC85B; NbExp=2; IntAct=EBI-602382, EBI-739674;
CC       Q16512; Q8IV13: CCNJL; NbExp=3; IntAct=EBI-602382, EBI-21668062;
CC       Q16512; Q01850: CDR2; NbExp=6; IntAct=EBI-602382, EBI-1181367;
CC       Q16512; Q86XR8-3: CEP57; NbExp=3; IntAct=EBI-602382, EBI-11752486;
CC       Q16512; Q8IYX8-2: CEP57L1; NbExp=3; IntAct=EBI-602382, EBI-10181988;
CC       Q16512; Q8NHQ1: CEP70; NbExp=3; IntAct=EBI-602382, EBI-739624;
CC       Q16512; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-602382, EBI-3867333;
CC       Q16512; Q9NRI5-2: DISC1; NbExp=3; IntAct=EBI-602382, EBI-11988027;
CC       Q16512; Q8WWB3: DYDC1; NbExp=3; IntAct=EBI-602382, EBI-740680;
CC       Q16512; P26641: EEF1G; NbExp=3; IntAct=EBI-602382, EBI-351467;
CC       Q16512; O00303: EIF3F; NbExp=3; IntAct=EBI-602382, EBI-711990;
CC       Q16512; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-602382, EBI-618189;
CC       Q16512; Q08379: GOLGA2; NbExp=6; IntAct=EBI-602382, EBI-618309;
CC       Q16512; A6NEM1: GOLGA6L9; NbExp=3; IntAct=EBI-602382, EBI-5916454;
CC       Q16512; P54257: HAP1; NbExp=3; IntAct=EBI-602382, EBI-712814;
CC       Q16512; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-602382, EBI-2514791;
CC       Q16512; Q9NSC5: HOMER3; NbExp=7; IntAct=EBI-602382, EBI-748420;
CC       Q16512; O75031: HSF2BP; NbExp=3; IntAct=EBI-602382, EBI-7116203;
CC       Q16512; Q9UKT9: IKZF3; NbExp=3; IntAct=EBI-602382, EBI-747204;
CC       Q16512; Q5TA45: INTS11; NbExp=3; IntAct=EBI-602382, EBI-748258;
CC       Q16512; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-602382, EBI-743960;
CC       Q16512; Q86T90: KIAA1328; NbExp=3; IntAct=EBI-602382, EBI-3437878;
CC       Q16512; P19012: KRT15; NbExp=3; IntAct=EBI-602382, EBI-739566;
CC       Q16512; P08779: KRT16; NbExp=3; IntAct=EBI-602382, EBI-356410;
CC       Q16512; P08727: KRT19; NbExp=3; IntAct=EBI-602382, EBI-742756;
CC       Q16512; Q15323: KRT31; NbExp=6; IntAct=EBI-602382, EBI-948001;
CC       Q16512; O76011: KRT34; NbExp=5; IntAct=EBI-602382, EBI-1047093;
CC       Q16512; Q92764: KRT35; NbExp=3; IntAct=EBI-602382, EBI-1058674;
CC       Q16512; O76013-2: KRT36; NbExp=3; IntAct=EBI-602382, EBI-11958506;
CC       Q16512; O76014: KRT37; NbExp=3; IntAct=EBI-602382, EBI-1045716;
CC       Q16512; Q9BV99: LRRC61; NbExp=3; IntAct=EBI-602382, EBI-2350424;
CC       Q16512; Q9NYL2-1: MAP3K20; NbExp=2; IntAct=EBI-602382, EBI-687346;
CC       Q16512; P53778: MAPK12; NbExp=2; IntAct=EBI-602382, EBI-602406;
CC       Q16512; O15344: MID1; NbExp=3; IntAct=EBI-602382, EBI-2340316;
CC       Q16512; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-602382, EBI-10172526;
CC       Q16512; Q8N108-16: MIER1; NbExp=3; IntAct=EBI-602382, EBI-25830642;
CC       Q16512; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-602382, EBI-2548751;
CC       Q16512; Q13064: MKRN3; NbExp=3; IntAct=EBI-602382, EBI-2340269;
CC       Q16512; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-602382, EBI-11522433;
CC       Q16512; P07196: NEFL; NbExp=3; IntAct=EBI-602382, EBI-475646;
CC       Q16512; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-602382, EBI-79165;
CC       Q16512; Q8ND90: PNMA1; NbExp=3; IntAct=EBI-602382, EBI-302345;
CC       Q16512; P78424: POU6F2; NbExp=3; IntAct=EBI-602382, EBI-12029004;
CC       Q16512; P28070: PSMB4; NbExp=3; IntAct=EBI-602382, EBI-603350;
CC       Q16512; Q96QF0-7: RAB3IP; NbExp=3; IntAct=EBI-602382, EBI-11984839;
CC       Q16512; Q9UJW9: SERTAD3; NbExp=3; IntAct=EBI-602382, EBI-748621;
CC       Q16512; Q9H7B4: SMYD3; NbExp=3; IntAct=EBI-602382, EBI-347919;
CC       Q16512; Q96R06: SPAG5; NbExp=3; IntAct=EBI-602382, EBI-413317;
CC       Q16512; Q9Y2D8: SSX2IP; NbExp=3; IntAct=EBI-602382, EBI-2212028;
CC       Q16512; Q9NZ72: STMN3; NbExp=3; IntAct=EBI-602382, EBI-725557;
CC       Q16512; O75558: STX11; NbExp=3; IntAct=EBI-602382, EBI-714135;
CC       Q16512; A1L190: SYCE3; NbExp=3; IntAct=EBI-602382, EBI-10283466;
CC       Q16512; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-602382, EBI-17438286;
CC       Q16512; Q13077: TRAF1; NbExp=3; IntAct=EBI-602382, EBI-359224;
CC       Q16512; Q12933: TRAF2; NbExp=3; IntAct=EBI-602382, EBI-355744;
CC       Q16512; P14373: TRIM27; NbExp=3; IntAct=EBI-602382, EBI-719493;
CC       Q16512; Q9BZW7: TSGA10; NbExp=3; IntAct=EBI-602382, EBI-744794;
CC       Q16512; Q8IWV8-2: UBR2; NbExp=3; IntAct=EBI-602382, EBI-17923957;
CC       Q16512; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-602382, EBI-739895;
CC       Q16512; P08670: VIM; NbExp=3; IntAct=EBI-602382, EBI-353844;
CC       Q16512; Q8TF47: ZFP90; NbExp=3; IntAct=EBI-602382, EBI-11419867;
CC       Q16512; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-602382, EBI-749023;
CC       Q16512; Q96MN9-2: ZNF488; NbExp=3; IntAct=EBI-602382, EBI-25831733;
CC       Q16512; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-602382, EBI-745520;
CC       Q16512; Q9UGI0: ZRANB1; NbExp=3; IntAct=EBI-602382, EBI-527853;
CC       Q16512; A1JU68: yopM; Xeno; NbExp=2; IntAct=EBI-602382, EBI-26365850;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17332740,
CC       ECO:0000269|PubMed:9478917}. Nucleus {ECO:0000269|PubMed:12514133}.
CC       Endosome {ECO:0000269|PubMed:9478917}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q63433}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q63433}. Cleavage furrow
CC       {ECO:0000269|PubMed:17332740}. Midbody {ECO:0000269|PubMed:17332740}.
CC       Note=Associates with chromatin in a ligand-dependent manner.
CC       Localization to endosomes is mediated via its interaction with RHOB.
CC       Association to the cell membrane is dependent on Ser-377
CC       phosphorylation. Accumulates during telophase at the cleavage furrow
CC       and finally concentrates around the midbody in cytokinesis.
CC       {ECO:0000250|UniProtKB:Q63433, ECO:0000269|PubMed:17332740}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16512-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16512-2; Sequence=VSP_038143;
CC       Name=3;
CC         IsoId=Q16512-3; Sequence=VSP_039213, VSP_039214;
CC   -!- TISSUE SPECIFICITY: Found ubiquitously. Expressed in heart, brain,
CC       placenta, lung, skeletal muscle, kidney and pancreas. Expressed in
CC       numerous tumor cell lines, especially in breast tumor cells.
CC       {ECO:0000269|PubMed:21754995}.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC   -!- PTM: Autophosphorylated; preferably on serine. Phosphorylated during
CC       mitosis. {ECO:0000269|PubMed:10792047, ECO:0000269|PubMed:17332740}.
CC   -!- PTM: Activated by limited proteolysis with trypsin. {ECO:0000250}.
CC   -!- PTM: (Microbial infection) In case of infection, polyubiquitinated by
CC       the bacterial E3 ubiquitin-protein ligase SspH1, leading to its
CC       proteasomal degradation. {ECO:0000269|PubMed:24248594}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D26181; BAA05169.1; -; mRNA.
DR   EMBL; S75546; AAB33345.1; -; mRNA.
DR   EMBL; U33053; AAC50209.1; -; mRNA.
DR   EMBL; AK123007; BAG53845.1; -; mRNA.
DR   EMBL; AK292130; BAF84819.1; -; mRNA.
DR   EMBL; AK313886; BAG36611.1; -; mRNA.
DR   EMBL; AC008569; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC040061; AAH40061.1; -; mRNA.
DR   EMBL; BC094766; AAH94766.1; -; mRNA.
DR   CCDS; CCDS42513.1; -. [Q16512-1]
DR   CCDS; CCDS42514.1; -. [Q16512-2]
DR   PIR; JC2129; JC2129.
DR   PIR; S51162; S51162.
DR   RefSeq; NP_002732.3; NM_002741.3. [Q16512-1]
DR   RefSeq; NP_998725.1; NM_213560.1. [Q16512-2]
DR   PDB; 1CXZ; X-ray; 2.20 A; B=13-98.
DR   PDB; 1URF; NMR; -; A=122-199.
DR   PDB; 2RMK; NMR; -; B=122-199.
DR   PDB; 4NKG; X-ray; 2.90 A; B/D=122-199.
DR   PDB; 4OTD; X-ray; 2.00 A; A=605-942.
DR   PDB; 4OTG; X-ray; 2.60 A; A=605-942.
DR   PDB; 4OTH; X-ray; 1.80 A; A=605-942.
DR   PDB; 4OTI; X-ray; 1.93 A; A=605-942.
DR   PDBsum; 1CXZ; -.
DR   PDBsum; 1URF; -.
DR   PDBsum; 2RMK; -.
DR   PDBsum; 4NKG; -.
DR   PDBsum; 4OTD; -.
DR   PDBsum; 4OTG; -.
DR   PDBsum; 4OTH; -.
DR   PDBsum; 4OTI; -.
DR   AlphaFoldDB; Q16512; -.
DR   SMR; Q16512; -.
DR   BioGRID; 111571; 129.
DR   CORUM; Q16512; -.
DR   DIP; DIP-34240N; -.
DR   ELM; Q16512; -.
DR   IntAct; Q16512; 96.
DR   MINT; Q16512; -.
DR   STRING; 9606.ENSP00000343325; -.
DR   BindingDB; Q16512; -.
DR   ChEMBL; CHEMBL3384; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q16512; -.
DR   GuidetoPHARMACOLOGY; 1520; -.
DR   GlyConnect; 1737; 1 N-Linked glycan (1 site).
DR   GlyGen; Q16512; 3 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (2 sites).
DR   iPTMnet; Q16512; -.
DR   MetOSite; Q16512; -.
DR   PhosphoSitePlus; Q16512; -.
DR   BioMuta; PKN1; -.
DR   DMDM; 259016304; -.
DR   EPD; Q16512; -.
DR   jPOST; Q16512; -.
DR   MassIVE; Q16512; -.
DR   MaxQB; Q16512; -.
DR   PaxDb; Q16512; -.
DR   PeptideAtlas; Q16512; -.
DR   PRIDE; Q16512; -.
DR   ProteomicsDB; 60877; -. [Q16512-1]
DR   ProteomicsDB; 60878; -. [Q16512-2]
DR   ProteomicsDB; 60879; -. [Q16512-3]
DR   Antibodypedia; 1296; 253 antibodies from 33 providers.
DR   DNASU; 5585; -.
DR   Ensembl; ENST00000242783.11; ENSP00000242783.7; ENSG00000123143.13. [Q16512-1]
DR   Ensembl; ENST00000342216.8; ENSP00000343325.4; ENSG00000123143.13. [Q16512-2]
DR   GeneID; 5585; -.
DR   KEGG; hsa:5585; -.
DR   MANE-Select; ENST00000242783.11; ENSP00000242783.7; NM_002741.5; NP_002732.3.
DR   UCSC; uc002myp.4; human. [Q16512-1]
DR   CTD; 5585; -.
DR   DisGeNET; 5585; -.
DR   GeneCards; PKN1; -.
DR   HGNC; HGNC:9405; PKN1.
DR   HPA; ENSG00000123143; Low tissue specificity.
DR   MIM; 601032; gene.
DR   neXtProt; NX_Q16512; -.
DR   OpenTargets; ENSG00000123143; -.
DR   PharmGKB; PA33769; -.
DR   VEuPathDB; HostDB:ENSG00000123143; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   GeneTree; ENSGT00940000154990; -.
DR   HOGENOM; CLU_000288_132_1_1; -.
DR   InParanoid; Q16512; -.
DR   OMA; CTELRIE; -.
DR   OrthoDB; 520651at2759; -.
DR   PhylomeDB; Q16512; -.
DR   TreeFam; TF102005; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; Q16512; -.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5625886; Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3.
DR   Reactome; R-HSA-8980692; RHOA GTPase cycle.
DR   Reactome; R-HSA-9013026; RHOB GTPase cycle.
DR   Reactome; R-HSA-9013106; RHOC GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   SABIO-RK; Q16512; -.
DR   SignaLink; Q16512; -.
DR   SIGNOR; Q16512; -.
DR   BioGRID-ORCS; 5585; 15 hits in 1115 CRISPR screens.
DR   ChiTaRS; PKN1; human.
DR   EvolutionaryTrace; Q16512; -.
DR   GeneWiki; Protein_kinase_N1; -.
DR   GenomeRNAi; 5585; -.
DR   Pharos; Q16512; Tchem.
DR   PRO; PR:Q16512; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q16512; protein.
DR   Bgee; ENSG00000123143; Expressed in apex of heart and 140 other tissues.
DR   ExpressionAtlas; Q16512; baseline and differential.
DR   Genevisible; Q16512; HS.
DR   GO; GO:0032154; C:cleavage furrow; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IDA:UniProtKB.
DR   GO; GO:0035402; F:histone kinase activity (H3-T11 specific); IDA:UniProtKB.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0030374; F:nuclear receptor coactivator activity; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004697; F:protein kinase C activity; EXP:Reactome.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031267; F:small GTPase binding; IDA:UniProtKB.
DR   GO; GO:0001783; P:B cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0010631; P:epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0060765; P:regulation of androgen receptor signaling pathway; TAS:Reactome.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0002634; P:regulation of germinal center formation; IEA:Ensembl.
DR   GO; GO:0002637; P:regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0003014; P:renal system process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   CDD; cd08687; C2_PKN-like; 1.
DR   CDD; cd11630; HR1_PKN1_2; 1.
DR   CDD; cd11622; HR1_PKN_1; 1.
DR   IDEAL; IID00416; -.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR037784; C2_PKN.
DR   InterPro; IPR011072; HR1_rho-bd.
DR   InterPro; IPR036274; HR1_rpt_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR037317; PKN1_HR1_2.
DR   InterPro; IPR037313; PKN_HR1_1.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF02185; HR1; 3.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00742; Hr1; 3.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF46585; SSF46585; 3.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS51860; REM_1; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Chromatin regulator; Coiled coil; Cytoplasm; Endosome;
KW   Kinase; Membrane; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..942
FT                   /note="Serine/threonine-protein kinase N1"
FT                   /id="PRO_0000055719"
FT   DOMAIN          25..100
FT                   /note="REM-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          112..193
FT                   /note="REM-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          201..280
FT                   /note="REM-1 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01207"
FT   DOMAIN          307..470
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          615..874
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          875..942
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          102..121
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          181..185
FT                   /note="Important for interaction with bacterial SspH1 and
FT                   SspH1-mediated polyubiquitination"
FT                   /evidence="ECO:0000269|PubMed:24248594"
FT   REGION          341..363
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          553..603
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        553..598
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        740
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         621..629
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         644
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            108..109
FT                   /note="Cleavage; by caspase-3"
FT   SITE            454..455
FT                   /note="Cleavage; by caspase-3"
FT   SITE            558..559
FT                   /note="Cleavage; by caspase-3"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         69
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         205
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q63433"
FT   MOD_RES         448
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         533
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         537
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         540
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         559
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         562
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         608
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         774
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:10792047"
FT   MOD_RES         778
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18220336"
FT   MOD_RES         914
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         916
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..7
FT                   /note="MASDAVQ -> MAEANNPSEQELE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038143"
FT   VAR_SEQ         603
FT                   /note="S -> R (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039213"
FT   VAR_SEQ         604..942
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039214"
FT   VARIANT         185
FT                   /note="R -> C (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs267605306)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042337"
FT   VARIANT         197
FT                   /note="A -> E (in dbSNP:rs1287763348)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042338"
FT   VARIANT         436
FT                   /note="R -> W (in dbSNP:rs35132656)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042339"
FT   VARIANT         520
FT                   /note="R -> Q (in dbSNP:rs56273055)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042340"
FT   VARIANT         555
FT                   /note="L -> I (in dbSNP:rs34309238)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042341"
FT   VARIANT         635
FT                   /note="R -> Q (in dbSNP:rs35416389)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042342"
FT   VARIANT         718
FT                   /note="I -> V (in dbSNP:rs2230539)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:7988719"
FT                   /id="VAR_042343"
FT   VARIANT         873
FT                   /note="F -> L (in a breast infiltrating ductal carcinoma
FT                   sample; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042344"
FT   VARIANT         901
FT                   /note="V -> I (in dbSNP:rs10846)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846"
FT                   /id="VAR_014937"
FT   VARIANT         921
FT                   /note="A -> V (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042345"
FT   MUTAGEN         108
FT                   /note="D->A: Abolishes cleavage by caspase-3 and formation
FT                   of AF1 fragment."
FT                   /evidence="ECO:0000269|PubMed:9751706"
FT   MUTAGEN         181
FT                   /note="R->A: Abolishes interaction with bacterial SspH1."
FT                   /evidence="ECO:0000269|PubMed:24248594"
FT   MUTAGEN         181
FT                   /note="R->K: Decreases interaction with bacterial SspH1."
FT                   /evidence="ECO:0000269|PubMed:24248594"
FT   MUTAGEN         185
FT                   /note="R->A: Abolishes interaction with bacterial SspH1."
FT                   /evidence="ECO:0000269|PubMed:24248594"
FT   MUTAGEN         451
FT                   /note="D->A: Abolishes cleavage by caspase-3 and formation
FT                   of 70 kDa fragment."
FT                   /evidence="ECO:0000269|PubMed:9751706"
FT   MUTAGEN         454
FT                   /note="D->A: Abolishes cleavage by caspase-3 and formation
FT                   of 70 kDa fragment."
FT                   /evidence="ECO:0000269|PubMed:9751706"
FT   MUTAGEN         558
FT                   /note="D->A: Abolishes cleavage by caspase-3 and formation
FT                   of AF3 fragment."
FT                   /evidence="ECO:0000269|PubMed:9751706"
FT   MUTAGEN         560
FT                   /note="D->A: Abolishes cleavage by caspase-3 and formation
FT                   of AF3 fragment."
FT                   /evidence="ECO:0000269|PubMed:9751706"
FT   MUTAGEN         644
FT                   /note="K->E: Abolishes Serine/threonine-protein kinase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:18066052,
FT                   ECO:0000269|PubMed:8135837"
FT   MUTAGEN         644
FT                   /note="K->R: Substantial reduction of autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:18066052,
FT                   ECO:0000269|PubMed:8135837"
FT   CONFLICT        191
FT                   /note="G -> D (in Ref. 2; AAB33345/AAC50209)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        562
FT                   /note="S -> P (in Ref. 3; BAG36611)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        736
FT                   /note="I -> T (in Ref. 6; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        750
FT                   /note="T -> A (in Ref. 6; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        800
FT                   /note="G -> A (in Ref. 6; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812
FT                   /note="E -> G (in Ref. 3; BAG36611)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        887
FT                   /note="L -> P (in Ref. 3; BAG53845)"
FT                   /evidence="ECO:0000305"
FT   HELIX           15..18
FT                   /evidence="ECO:0007829|PDB:1CXZ"
FT   HELIX           29..66
FT                   /evidence="ECO:0007829|PDB:1CXZ"
FT   HELIX           71..95
FT                   /evidence="ECO:0007829|PDB:1CXZ"
FT   TURN            122..124
FT                   /evidence="ECO:0007829|PDB:1URF"
FT   HELIX           126..151
FT                   /evidence="ECO:0007829|PDB:4NKG"
FT   TURN            157..159
FT                   /evidence="ECO:0007829|PDB:4NKG"
FT   HELIX           160..187
FT                   /evidence="ECO:0007829|PDB:4NKG"
FT   STRAND          194..196
FT                   /evidence="ECO:0007829|PDB:2RMK"
FT   HELIX           612..614
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          615..624
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          627..634
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            635..637
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          640..647
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           648..653
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           657..671
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            672..674
FT                   /evidence="ECO:0007829|PDB:4OTG"
FT   STRAND          681..686
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          688..696
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          700..702
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           703..706
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            707..709
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           714..733
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           743..745
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          746..748
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          750..752
FT                   /evidence="ECO:0007829|PDB:4OTG"
FT   STRAND          754..756
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   STRAND          763..765
FT                   /evidence="ECO:0007829|PDB:4OTD"
FT   HELIX           779..781
FT                   /evidence="ECO:0007829|PDB:4OTD"
FT   HELIX           784..788
FT                   /evidence="ECO:0007829|PDB:4OTD"
FT   HELIX           794..810
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           820..829
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           840..849
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            854..856
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            862..864
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           865..869
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           872..874
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           879..883
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           906..909
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   HELIX           926..930
FT                   /evidence="ECO:0007829|PDB:4OTH"
FT   TURN            931..934
FT                   /evidence="ECO:0007829|PDB:4OTH"
SQ   SEQUENCE   942 AA;  103932 MW;  61360295EC70BB8E CRC64;
     MASDAVQSEP RSWSLLEQLG LAGADLAAPG VQQQLELERE RLRREIRKEL KLKEGAENLR
     RATTDLGRSL GPVELLLRGS SRRLDLLHQQ LQELHAHVVL PDPAATHDGP QSPGAGGPTC
     SATNLSRVAG LEKQLAIELK VKQGAENMIQ TYSNGSTKDR KLLLTAQQML QDSKTKIDII
     RMQLRRALQA GQLENQAAPD DTQGSPDLGA VELRIEELRH HFRVEHAVAE GAKNVLRLLS
     AAKAPDRKAV SEAQEKLTES NQKLGLLREA LERRLGELPA DHPKGRLLRE ELAAASSAAF
     STRLAGPFPA THYSTLCKPA PLTGTLEVRV VGCRDLPETI PWNPTPSMGG PGTPDSRPPF
     LSRPARGLYS RSGSLSGRSS LKAEAENTSE VSTVLKLDNT VVGQTSWKPC GPNAWDQSFT
     LELERARELE LAVFWRDQRG LCALKFLKLE DFLDNERHEV QLDMEPQGCL VAEVTFRNPV
     IERIPRLRRQ KKIFSKQQGK AFQRARQMNI DVATWVRLLR RLIPNATGTG TFSPGASPGS
     EARTTGDISV EKLNLGTDSD SSPQKSSRDP PSSPSSLSSP IQESTAPELP SETQETPGPA
     LCSPLRKSPL TLEDFKFLAV LGRGHFGKVL LSEFRPSGEL FAIKALKKGD IVARDEVESL
     MCEKRILAAV TSAGHPFLVN LFGCFQTPEH VCFVMEYSAG GDLMLHIHSD VFSEPRAIFY
     SACVVLGLQF LHEHKIVYRD LKLDNLLLDT EGYVKIADFG LCKEGMGYGD RTSTFCGTPE
     FLAPEVLTDT SYTRAVDWWG LGVLLYEMLV GESPFPGDDE EEVFDSIVND EVRYPRFLSA
     EAIGIMRRLL RRNPERRLGS SERDAEDVKK QPFFRTLGWE ALLARRLPPP FVPTLSGRTD
     VSNFDEEFTG EAPTLSPPRD ARPLTAAEQA AFLDFDFVAG GC
//
